Neuronetics

Neuronetics EBITDA

Vrijednost EBITDA (Заработак пре камата, пореза, амортизације и отписивања) od Neuronetics (STIM) na dan 4. нов 2026. je -30,60 М USD. Prethodne godine, EBITDA (Заработак пре камата, пореза, амортизације и отписивања) je bio -36,44 М USD — promjena od -16,03% (viši).

EBITDA

-30,60 МUSD

YoY

-16,03%

Zadnja ažuriranja:

EBITDA (Заработак пре камата, пореза, амортизације и отписивања) od Neuronetics je 2025 -30,60 М USD. EBITDA (Заработак пре камата, пореза, амортизације и отписивања) od Neuronetics je bio 2024 -36,44 М USD. Pad je time -16,03% viši u odnosu na prethodnu godinu.

Istorija Neuronetics EBITDA

  • 3 године

  • 10 година

  • 25 godina

  • Максимално

EBITDA
Datum
EBITDA
1. јан 2018.
-20,41 М USD
1. јан 2019.
-28,26 М USD
1. јан 2020.
-22,93 М USD
1. јан 2021.
-27,87 М USD
1. јан 2022.
-33,61 М USD
1. јан 2023.
-30,55 М USD
1. јан 2024.
-36,44 М USD
1. јан 2025.
-30,60 М USD
Istorija Neuronetics EBITDA
ГОДИНАEBITDAYoY
-30,60 МUSD-16,03%
-36,44 МUSD+19,27%
-30,55 МUSD-9,09%
-33,61 МUSD+20,57%
-27,87 МUSD+21,56%
-22,93 МUSD-18,85%
-28,26 МUSD+38,46%
-20,41 МUSD+54,02%
-13,25 МUSD+41,92%
-9,34 МUSD—

Pristupite ovim podacima preko Eulerpool API-ja

100.000 zahteva/mes. besplatno · bez kartice

Neuronetics Анализа акција

Šta radi Neuronetics? Neuronetics Inc is a globally leading company in the field of non-invasive neuromodulatory technology. It was founded in 2003 and is headquartered in Malvern, Pennsylvania. The company specializes in the development and production of transcranial magnetic stimulation devices that can be used in the treatment of psychiatric disorders, particularly severe depression. Neuronetics' business model is based on selling its patented technology, called NeuroStar Advanced Therapy, to medical facilities worldwide. The company works closely with leading psychiatrists and clinical neurophysiologists to ensure that their devices meet the highest quality standards and can provide the best possible help to patients. The company has achieved a number of significant milestones in recent years. For example, in 2008, it received the first FDA approval for its technology. Since then, Neuronetics has continuously developed and improved its technology and has also obtained approvals in Europe and other parts of the world. Neuronetics is divided into various divisions, including research and development, manufacturing, and sales. Each of these departments is focused on ensuring the highest quality standards and ensuring that the technology of NeuroStar Advanced Therapy meets the needs of patients and medical personnel. The technology of NeuroStar Advanced Therapy is based on transcranial magnetic stimulation (TMS), which uses gentle magnetic fields to stimulate the activity of certain brain regions. The stimulation can help restore the balance of neurotransmitters in the brain and thus alleviate depression. Treatment with NeuroStar Advanced Therapy has significant advantages over conventional antidepressant medications. In many cases, it leads to faster improvement of symptoms and does not cause any of the undesirable side effects that can occur with medication. Overall, Neuronetics has developed a revolutionary technology with NeuroStar Advanced Therapy that can help millions of people around the world overcome their depression. The company is proud to contribute to improving the quality of life for people and will continue to develop innovative solutions in the field of neuromodulatory technology in the future. Neuronetics je jedna od najpopularnijih kompanija na Eulerpool.

Često postavljena pitanja o akciji Neuronetics

EBITDA (Заработак пре камата, пореза, амортизације и отписивања) kompanije Neuronetics iznosi -30,60 М USD u 2025. godini.

EBITDA (Заработак пре камата, пореза, амортизације и отписивања) od Neuronetics se promijenio sa -36,44 М USD na -30,60 М USD, što predstavlja promjenu od -16,03%. Vrijednost je viši nego prethodne godine.

Na Eulerpool-u možete pronaći potpuni historijski razvoj EBITDA (Заработак пре камата, пореза, амортизације и отписивања) Neuronetics od 2006. — sa godišnjim vrijednostima, grafikonima i detaljnom analizom.

EBITDA мери оперативну перформансу пре утицаја финансијске структуре, окружења пореза и не-готовинских отписивања.

EBITDA = EBIT + Амортизација и отписивање

EBITDA (Заработак пре камата, пореза, амортизације и отписивања)'s USD je ključan faktor za investitore. Promene u ovoj metrici mogu signalizirati poboljšane ili pogoršane fundamentalne faktore, direktno utiču na cenu akcije. Na Eulopoolu, možete pratiti EBITDA (Заработак пре камата, пореза, амортизације и отписивања)'s Neuronetics istorijski i u realnom vremenu.

Pristupite ovim podacima preko Eulerpool API-ja

100.000 zahteva/mes. besplatno · bez kartice

Извештај о добити и губитку — Neuronetics

Sve ključne metrike — Neuronetics

Раст